KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Net Margin: 2009-2025

Historic Net Margin for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Sep 2025 value amounting to 20.10%.

  • Alnylam Pharmaceuticals' Net Margin rose 4238.00% to 20.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.65%, marking a year-over-year increase of 1751.00%. This contributed to the annual value of -12.37% for FY2024, which is 1171.00% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Net Margin stood at 20.10%, which was up 334.67% from -8.57% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Net Margin's 5-year high stood at 20.10% during Q3 2025, with a 5-year trough of -191.60% in Q1 2025.
  • Its 3-year average for Net Margin is -35.01%, with a median of -14.12% in 2024.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 17,327bps in 2023, then crashed by 17,826bps in 2025.
  • Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Net Margin stood at -99.97% in 2021, then surged by 3,804bps to -61.93% in 2022, then spiked by 3,058bps to -31.35% in 2023, then soared by 1,723bps to -14.12% in 2024, then skyrocketed by 4,238bps to 20.10% in 2025.
  • Its last three reported values are 20.10% in Q3 2025, -8.57% for Q2 2025, and -191.60% during Q1 2025.